Triana Biomedicines, Inc. — Form D
Triana Biomedicines, Inc. of LEXINGTON, MA, a company, filed a Form D exempt-offering notice with the SEC on 2022-02-11. The offering totals $80.0M, of which $34.8M was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2022-02-11
- Form: D
- Accession: 0001815337-22-000002
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $80.0M
- Amount sold: $34.8M
- Remaining: $45.2M
- Investors: 12
- Date of first sale: 2022-01-28
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-433414
Issuer
- Name: Triana Biomedicines, Inc.
- CIK: 0001815337
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2019
- Address: 1050 WALTHAM STREET, LEXINGTON, MA, 02421
- Phone: 781-317-4414
Officers, directors & promoters (15)
| Name | Role | Location |
|---|
| Andrew Levin | Director | BOSTON, MA |
| Christopher O'Donnell | Director | Kingston, RI |
| Patrick Trojer | Director | Lexington, MA |
| Patrick Trojer | Executive Officer | Lexington, MA |
| Joshua Resnick | Director | New York, NY |
| Jigar Raythatha | Director | Boston, MA |
| David Grayzel | Director | Cambridge, MA |
| Andrew Hedin | Director | Claymont, DE |
| Lorence Kim | Director | Lexington, MA |
| Shelley Chu | Director | Lexington, MA |
| MILIND DESHPANDE | Director | WALTHAM, MA |
| MILIND DESHPANDE | Executive Officer | WALTHAM, MA |
| Simon Read | Director | Waltham, MA |
| Christopher O'Donnel | Director | Waltham, MA |
| Nathaniel Brooks Horwitz | Director | Boston, MA |
Other filings by this issuer (4)
More